GlaxoSmithKline are set to make redundancies at their site in Stevenage. The move comes as the firm takes "a new approach to research and development," in focusing more strongly on "transformational medicines."

As explained by a GSK spokesperson at the Gunnels Wood Road site: "Since we announced our new approach to research and development in 2018, the future direction of our portfolio has become clearer, prioritising innovation and moving towards delivering a pipeline of transformational medicines with a focus on immunology, genetically validated targets, and finding platforms and technologies that amplify our science."

A company spokesperson said just "a small number of roles" would be directly impacted.

"We have identified where changes are necessary to ensure we can fully support our evolving pipeline priorities. We anticipate a small number of roles will be directly impacted by these changes but continue to expect GSK's R&D operations to grow overall with increased investment."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.